FDA green and red lights: April 2024
A tumour-agnostic label for Enhertu leads April’s US oncology approvals.
BridgeBio’s oncology spinout must stand out from the crowd
The new developer will focus on the crowded KRAS space and PI3Kα/AKT inhibition, which has been hit by toxicity issues.
Enhertu pushes on the HER2-low door once again
Daiichi and AstraZeneca claim another breast cancer success, and further evidence of the ADC’s activity in very low HER2 expression.
ASCO 2024 preview – Astra’s plenary double
Abstract titles reveal some of ASCO’s key datasets.
Third time lucky for Roche in MAGE-A4?
The Swiss company is still interested in this antigen, after discontinuing two earlier clinical projects.
Roche trims its pipeline again
Belvarafenib heads back to Hanmi and LY6G6D targeting takes a blow.
